Skip to main content

Industry News

  • Zydus and Bayer announce continuity of their successful Joint Venture

    Bayer Pte Ltd and Cadila Healthcare Limited announced the extension of their Joint Venture by three years from June 2021. The companies first entered into an agreement on January 28, 2011 to set up the Joint Venture - Bayer Zydus Pharma Private Limited for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai.

  • Empagliflozin approved in Europe for the treatment of heart failure

    Todays approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and more time with their families.

  • Medtronic launches smallest pacemaker with Atrioventricular synchrony

    India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of Micra AV - a miniaturized, fully self-contained pacemaker that delivers advanced pacing technology to atrioventricular (AV) block patients via a minimally invasive approach. The device is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart

  • Glenmark launches bioequivalent of Tiotropium Bromide for treatment of COPD

    Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

  • NATCO receives approval for Carfilzomib Vials ANDA in the US market

    Natco Pharma Limited is pleased to announce that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received approval for its Abbreviated New Drug Application (ANDA) for Carfilzomib Vials ANDA (generic for KYPROLIS), from the U.S. Food and Drug Administration (USFDA).

  • Indian Pharmaceutical industry affected by counterfeiting challenges

    Indian Pharmaceutical industry amongst five sectors affected by counterfeiting Incidents reported by Authentication Solution Providers Association, ASPA. There was a sharp spike in crimes related to illicit liquor, smuggling of tobacco products and pharmaceutical products especially PPE kits and sanitizers, etc during the COVID-19 lockdown.

  • Abbott Receives European and Canadian approval for Amplatzer

    Abbott announced it has received CE Mark and Health Canada approval for its Amplatzer™ Steerable Delivery Sheath, which is used with the company's market-leading Amplatzer Amulet™ Left Atrial Appendage (LAA) Occluder. Now available in Europe and Canada, the new device is the first steerable delivery sheath that has been developed specifically for minimally invasive LAA occlusion (or closure) procedures to treat patients diagnosed with atrial fibrillation who are at risk of ischemic stroke.

  • Haffkine Biopharma to produce Covaxin under technology transfer

    Haffkine Biopharma to produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech With the aim of vaccinating the entire eligible population at the earliest, domestic vaccine production is being steadily ramped up in the country with help from the Centre. As part of this initiative, three public enterprises are being supported by  the Department of Biotechnology under Atmanirbhar Bharat 3.0  Mission Covid Suraksha. 

  • Lupin Launches Authorized Generic Version of Brovana in the United States

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

    Global pharma major, Lupin Limited (Lupin), announced the launch of the authorized generic version of Brovana® (arformoterol tartrate) Inhalation Solution 15 mcg/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc.

  • Olympus Acquires Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth

    Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of BPH. The company’s flagship product iTind has received U.S. FDA de Novo authorization and a European CE mark. With its initial Medi-Tate investment, Olympus has had the right of distribution since November 2018.

Subscribe to Industry News